肩关节置换术后症状性血栓栓塞并发症:更新
该研究回顾16年间5906例肩关节置换患者,症状性静脉血栓栓塞(VTE)发生率为0.41%,无VTE相关死亡。年龄>70岁和创伤指征为独立危险因素,VTE患者住院时间更长且再入院率更高。结论认为常规药物预防可能不必要,但高危患者应考虑药物预防。
要点
- 肩关节置换术后症状性VTE发生率为0.41%,无VTE相关死亡。
- 年龄>70岁和创伤指征是VTE的独立危险因素。
- VTE患者住院时间延长且再入院风险增加,高危患者应考虑药物预防。
核心结论
- 肩关节置换术后VTE风险低,常规药物预防可能不必要。
- 但VTE可导致显著并发症、住院时间延长和再入院,高危患者应考虑药物预防。
研究设计与样本
- 回顾性研究,纳入16年间5906例初次解剖型全肩关节置换、反式全肩关节置换或半肩关节置换患者。
- 在术后90天内识别出24例肩关节出现症状性VTE事件。
主要发现
- 症状性VTE发生率为0.41%。
- VTE患者年龄大于无VTE患者(74.75岁 vs 68.51岁;p=0.0028)。
- VTE患者中创伤指征比例高于无VTE患者(3.31% vs 0.33%;p<0.001)。
- 多因素logistic回归显示年龄>70岁和创伤指征为独立危险因素,而BMI、性别、手术时间和置换类型不是独立危险因素。
- VTE事件直接导致11例再入院,住院患者中诊断VTE者住院时间长于门诊患者(13.71天 vs 1.94天;p=0.0002)。
关键数值与推荐
- 症状性VTE发生率为0.41%(24/5906)。
- 年龄>70岁和创伤指征为独立危险因素(多因素分析)。
- 对于有多个VTE危险因素(如既往VTE史、活动性恶性肿瘤、年龄>70岁或创伤指征)的患者,应考虑药物VTE预防。
临床怎么用
- 肩关节置换术后常规药物VTE预防可能不必要。
- 对于年龄>70岁或创伤指征等高危患者,应考虑药物VTE预防。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) complications, including deep vein thrombosis and pulmonary embolism, are dreaded complications of orthopaedic surgical procedures that can result in substantial morbidity and mortality. There is a paucity of data examining risk factors for VTE in shoulder arthroplasty. The purpose of the present study was to review the rate of symptomatic VTE, determine patient and operative risk factors for VTE, and report on complications associated with VTE following shoulder arthroplasty. METHODS: Over a 16-year period, 5,906 patients underwent primary anatomic total shoulder arthroplasty, reverse total shoulder arthroplasty, or hemiarthroplasty. Symptomatic VTE events were identified in 24 shoulders within 90 days of surgery. Patient records were reviewed for surgical indication, patient and operative risk factors, and management of VTE. RESULTS: The rate of symptomatic VTE following shoulder arthroplasty was 0.41%. There were no deaths resulting from VTE events. Compared with patients who did not have VTE, those with symptomatic VTE events were found to be older (74.75 versus 68.51 years; p = 0.0028) and more likely to have had arthroplasty for a traumatic indication (3.31% versus 0.33%; p < 0.001). Age of >70 years and arthroplasty for a traumatic indication were found to be independent risk factors on multivariate nominal logistic regression analysis, whereas body mass index, sex, operative time, and type of arthroplasty performed were not found to be independent risk factors. There were 11 readmissions resulting directly from the VTE events, and patients diagnosed with VTE as inpatients had longer hospital stays than outpatients (13.71 versus 1.94 days; p = 0.0002). CONCLUSIONS: The risk of VTE following shoulder arthroplasty is low, and routine use of pharmacologic VTE prophylaxis may not be necessary. However, VTE complications can lead to substantial morbidity, longer hospital stays, readmission to the hospital, and further complications. Therefore, patients with multiple risk factors for VTE such as prior history of VTE, active malignancy, age of >70 years, or arthroplasty for traumatic indications should be considered for pharmacologic VTE prophylaxis. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
引用
- Kolz JM, Aibinder WR, Adams RA, et al. Symptomatic Thromboembolic Complications After Shoulder Arthroplasty: An Update. J Bone Joint Surg Am. 2019. PMID: 31626009. doi:10.2106/JBJS.18.01200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。